



## Common allergy problems and Drug allergy

ผศ. พญ. ทิชา ฤกษ์พัฒนาพัฒน์  
อนุสาวาติคณิตแพทย์วินิทยาและโรคข้อ<sup>ก</sup>  
ภาควิชาอาชญาศาสตร์ รพ.รามคำแหง



## OUTLINE

- Allergic/ hypersensitivity reaction
  - Specific immune response to allergen: immediate (IgE-mediated), delayed (T cell-mediated, IgG-, eosinophil-, etc)
- IgE-mediated allergic disease
  - Immediate systemic reaction: Anaphylaxis
  - Chronic allergic diseases: Allergic rhinitis, asthma, atopic dermatitis, conjunctivitis
- Urticaria, angioedema
  - Multi-mechanism, mostly non-specific histamine release
- Delayed-type HSR (T cell-mediated)
  - Drug exanthem, SJS-TEN, DRESS

SJS, Stevens-Johnson syndrome  
TEN, toxic epidermal necrolysis  
DRESS, drug reaction with eosinophilia and systemic symptoms



## CUTANEOUS ADVERSE DRUG REACTION (CADR)

T cell-mediated, delayed-type  
hypersensitivity (DTH)



## Clinical Classification of Drug Allergy


	Immediate	Nonimmediate
■ Onset	< 1 hour	>1 hour (usu. >24 hr)
■ Mechanism	Mostly IgE-mediated	T cell-mediated
■ Cutaneous	Urticaria, angioedema	Maculopapular rash, bullous, pustular
■ Systemic symptoms & signs	Hypotension, wheezing, dyspnea, diarrhea	Fever, hepatitis, nephritis, pneumonitis Hematologic involvement

Demoly P, Bousquet J. Allergy 2002; 57 (suppl.72):37-40



## Nonimmediate (mostly T cell-mediated)

### Visible



### Not visible:

- Fever
- Hepatitis
- Cytopenia
- Leukocytosis, eosinophilia
- Nephritis
- Pneumonitis
- Internal organ vasculitis

Physical exam: V/S,  
mucous membrane  
Lab: CBC, LFT, UA,  
BUN, Cr, CXR



## Patch test

Diagnosis of type IV (T cell-mediated) DTH



Read at 48, 96 hours



## Intradermal test (IDT) – delayed reading


- Perform intradermal skin test
- Delayed reading (48 h up to 7 days): eczema, infiltrative lesion



Confirm Type IV, T cell-mediated delayed typed HSR




## 37 year female with relapse AML (maculopapular exanthem; MPE)



## 4 months later: β-lactam testing

- Relapse AML after SCT 5 yr, S/P chemoRx → CR
- Suspected drug reaction
  - MPE from meropenem (d9), vancomycin (d6)
  - papule from Tazocin (d9)
  - MPE from doripenem (d2)
- ST pen/pip-tazo/carbapenem (delayed-reading) :
  - Positive pip/tazo
- DPT meropenem: negative
- DPT vancomycin: negative



Infiltrative papule at pip/tazo 20 hr after testing



## 4 months later: β-lactam testing


- Diagnosis: type IV HSR to piperacillin/tazobactam
- History of MPE (meropenem and vancomycin) can be excluded
  - MPE from doripenem (d2)
- ST pen/pip-tazo/carbapenem (delayed-reading) :
  - Positive pip/tazo
- DPT meropenem: negative
- DPT vancomycin: negative



Infiltrative papule at pip/tazo 20 hr after testing



## Severe Cutaneous Adverse Reaction (SCAR)




Only 'early withdrawal of suspected drug' could decrease mortality rate<sup>1</sup> Importance of early diagnosis!

<sup>1</sup> Garcia-Daval I, et al. Arch Dermatol 2002; 136:323-7.  
SJS-TEN, Stevens-Johnson syndrome; AGEP, acute generalized exanthematous pustulosis  
DRESS, drug reaction with eosinophilia and systemic symptoms



## Red flag Symptoms & Signs for non-immediate HSR




 **54 year male, eye pain and lip swelling 2 days → rash**

**2 days ago: eye & lip pain with lip swelling, Rx: amoxycillin, idarac, steroid E.D. → next day: generalized rash**

- PH: Gout for 4 months colchicine- rash
- Current Rx (3 weeks ago): celecoxib as needed, allopurinol (300) 1x1

**Mucous mb ulceration**

**Diagnosis: SJS (allopurinol day 21)**



 **Clinical Classification of SJS-TEN**

	Pattern of lesions	Distribution	Extent of blisters / Detachment %	Mortality
Erythema Multiforme major (EMM)	Raised (typical or atypical targets)	Localized (acral)	< 10	0%
SJS	Flat atypical targets or Blister on macules	Widespread	< 10	10%
Overlap SJS-TEN	Flat atypical targets or Blister on macules	Widespread	10-29	10-30%
TEN with spots	Flat atypical targets or Blister on macules	Widespread	≥ 30	30+%
TEN without spots	no discrete lesion, Large erythematous area	Widespread	≥ 10	30+%

 Bastuji-Garin S, .... and Roujeau J-C. Arch Dermatol 1993; 129:92-96.

 **Clinical Classification of SJS-TEN**

**Recognition 2 common skin eruption in SJS-TEN:**  
Macule and atypical target  
All with epidermal necrolysis (bleb or detachment)

Erythema Multiforme major (EMM)	Raised (typical or atypical targets)	Localized (acral)	< 10	0%
SJS	Flat atypical targets or Blister on macules	Widespread	< 10	10%
Overlap SJS-TEN	Flat atypical targets or Blister on macules	Widespread	10-29	10-30%
TEN with spots	Flat atypical targets or Blister on macules	Widespread	≥ 30	30+%
TEN without spots	no discrete lesion, Large erythematous area	Widespread	≥ 10	30+%

 Bastuji-Garin S, .... and Roujeau J-C. Arch Dermatol 1993; 129:92-96.

 **Importantly 'mucous membrane involvement'**

**Common feature of both EMM and SJS-TEN**




 **EMM (Erythema multiforme major)**



- 'Iris' lesion: circular, raised, 3 zones lesion
- Typically acrally localized
- Association with viral infection
- No mortality

 **Purpuric Macules in SJS**



- Most common in SJS-TEN
- Flat, purpuric macules
- Irregular shaped
- May develop confluent erythema → epidermal necrolysis and detachment
- Early sign = Nikolsky's sign

**Female with fever, exanthema eruption, oral and eye pain for 4 days**

**Atypical target/macule with blister (epidermal necrolysis)**

**Positive Nikolsky's sign**

**Diagnosis: TEN (etoricoxib day 15)**

**Large sheet of epidermal necrolysis (TEN)**

**50 year male with fever, diarrhea, pruritic rash and jaundice for 6 days**

**RA (1<sup>st</sup> diagnosis): SSZ, etoricoxib, CQ, pred, INH, OMZ for 6 wks MTX, folic for 4 days**

**T 38.3 C, BP 130/90 mmHg, HR 110/min, RR 20/min**  
**Face swelling and confluent maculopapular eruption**

**CBC: Hct 41%, WBC 22,700 (N56%, L17%, M 12%, E14%)**  
**Plt 159,000/mm<sup>3</sup>**

**LFT: AST 52, ALT 72, AP 735, GGT 874 U/L, TB 6.7, DB 4.8 mg/dl**

**UA: Sp gr 1.025, prot 2+, WBC 10-15, no eosinophil, RBC 2-3, granular cast 2-4, waxy cast 0-1, epith 5-10/HPF**  
**BUN 23 mg/dl, Cr 1.2 mg/dl**

**Diagnosis: DRESS (likely sulfasalazine)**

**Criteria for DIHS/DRESS**  
Modified from J-SCAR and EuroSCAR

**1. MP rash begins > 3 wks after initiation of drug**  
▪ Suggestive: BSA > 50%, facial swelling, exfoliative dermatitis **2**

**2. Prolonged clinical symptoms > 2 wks after stop the drug**

**3. Fever (> 38 C)**

**4. Transaminase > 100 U/L [2x of normal value] **1****

**5. Leukocyte abnormalities (at least one)**  
▪ Leukocytosis (> 11,000 cell/mm<sup>3</sup>) [high or lower than norm] **1**  
▪ Atypical lymphocytosis (> 5%) [any %] **1**  
▪ Eosinophilia (> 1,500 cell/mm<sup>3</sup>) [ $> 10\text{-}20\%$ , AEC > 700-1500] **2**

**6. Lymphadenopathy **1****

**7. HHV 6 reactivation**

**Score 4-5 (probable)**  
 **$\geq 6$  (definite)**

Shiohara T et al. Br J of Dermatol 2007; 156:1045-1092.  
Kardaun SH, et al. Br J Dermatol 2007; 156: 609-611.

**Common Drug Lists**

**SJS/TEN**

- Allopurinol
- Carbamazepine
- Phenytoin
- Phenobarbital
- Lamotrigine
- Sulfamethoxazole
- Nevirapine
- Oxicam, coxib?

**DRESS**

- Anti-convulsant
  - Carbamazepine
  - Phenytoin
  - Phenobarbital
  - Lamotrigine
- Allopurinol
- Sulfonamides
  - Sulfasalazine, dapsone
- Abacavir, nevirapine
- Minocycline, vancomycin

Roujeau JC, et al. N Engl J Med 1995;333:1600-7.

**Take Home Message**

- Hypersensitivity: excessive function → autoimmune disease, allergic disease
- Allergy (Type I, IgE-mediated immeditated HSR)
  - Systemic: Anaphylaxis → adrenaline IM
  - Chronic inflammation: AR, asthma → topical steroid
- Pseudoallergy: pre-meds + slow rates
  - Isolated angioedema: look for drug (ACE-I, NSAIDs)
- Delayed (Type IV, T-cell mediated)
  - Maculopapular exanthem: avoid
  - SJS-TEN, DRESS: early recognition, avoid
  - Culprit: allopurinol, antiepileptic drug, sulfonamide, anti-retroviral drug

• V/S, mucous mb, epidermal necrolysis  
• CBC, LFT, UA, CXR  
• Daily visit

**Question?**

**Thank you  
For Your Attention**